

MenB Vaccines

Vaccine	Recommend Age	Dosage	Dosing Schedule
MenB-FHbp (Trumenba) <i>Wyeth</i>	10 years and older	0.5 mL	Three doses, at least one month apart (0, 2, and 6 month schedule)
MenB-4C (Bexsero®) <i>Novartis</i>		single dose pre-filled syringes	Two doses at least 1 month apart (0 and 1-6 month schedule)

Meningococcal Serogroup B Vaccine Recommendations

- Certain persons aged 10 years and older who are at increased risk for meningococcal disease attributable to serogroup B, including:
 - Persons with persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D or taking eculizumab (Soliris®))
 - Persons with anatomic or functional asplenia, including sickle cell disease.
 - Microbiologists routinely exposed to isolates of *Neisseria meningitidis*.
 - Persons identified as at increased risk because of a serogroup B meningococcal disease outbreak.
 - Persons residing on college campuses that have recently experienced an outbreak of serogroup B meningococcal disease.
- A MenB vaccine series may be administered to adolescents and young adults aged 16-23 years to provide short-term protection against most strains of serogroups B meningococcal disease.
- The preferred age for MenB vaccination is 16-18 years.
- MenB vaccine should be used during pregnancy **only** if clearly indicated.
- MenB vaccines are not licensed for children aged <10 years and are not currently recommended for children aged 2 months–9 years who are at increased risk for serogroup B meningococcal disease.
- MenB vaccine **is not** recommended for the following persons:
 - Travelers to or persons residing in countries where meningococcal disease is hyperendemic or epidemic because the risk for meningococcal disease in these countries generally is not caused by serogroup B.
 - First year college students living in residence halls or military recruits.



Contraindications

- **MenB-FHbp (Trumenba):** severe allergic reaction after a previous dose.
- **MenB-4C (Bexsero):** hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose.

Precautions

- **MenB-FHbp (Trumenba) and MenB-4C (Bexsero):** individuals with altered immunocompetence may have reduced immune responses to MenB vaccines.

COM-PR/B71-VMB-V1 (11/17/15)

Vaccine Administration:

MenB-FHbp (Trumenba) and MenB-4C (Bexsero)

- MenB vaccine should be administered as either a 2-dose series of MenB-4C or a 3-dose series of MenB-FHbp.
- The same vaccine product should be used for all doses.
- Shake syringe vigorously to ensure that a homogenous white suspension is obtained. Do not use the vaccine if it cannot be re-suspended.
- Inspect visually for particulate matter and discoloration prior to administration, whenever solution and container permit; do not use if particulate matter or discoloration is found.
- Administer as a 0.5 mL dose using a sterile needle attached to the supplied prefilled syringe.
- The preferred site for injection is the deltoid muscle of the upper arm.
- Do not mix with any other vaccine in the same syringe
- May be administered simultaneously with other vaccines but in a separate injection site.

Adverse Reactions

- MenB-FHbp (Trumenba):
Local: injection site pain
Systemic: fatigue, headache, muscle pain, chills
- MenB-4C (Bexsero):
Local: injection site pain, erythema
Systematic: fatigue, headache, nausea, arthralgia, myalgia

Vaccine Storage and Handling

- Store refrigerated, at 36°F to 46°F (2°C to 8°C).
- Do not freeze. Discard if the vaccine has been frozen.
- Protect from light.